Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides our company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
- Progenitor Cell Therapy, LLC (PCT), our wholly owned subsidiary, is a leading CDMO in the cellular therapy industry.
- Our wholly-owned subsidiary, Amorcyte, LLC (Amorcyte) is developing our proprietary cell therapy, AMR-001, for the treatment of cardiovascular disease.
- Through our majority-owned subsidiary, Athelos Corporation (Athelos), we are collaborating with Becton-Dickinson in early stage clinical development of a cellular therapy utilizing T-cells, for autoimmune and inflammatory conditions.
- Our pre-clinical assets include our VSEL™ (very small embryonic-like) Technology platform for which we expect to file an Investigational New Drug (“IND”) with the FDA to initiate a National Institutes of Health funded human clinical study treating periodontitis with VSELs.
We believe that NeoStem is ideally positioned to be an integrated leader in the cell therapy industry. We have significant basic research and development capabilities, manufacturing and processing facilities on both the East and West Coasts of the United States, as well as talented and experienced management and clinical teams. We believe these capabilities will allow us to achieve our mission of becoming the premier cell therapy company.
Thank you for visiting the NeoStem website and please read on to learn more.
Robin L. Smith, M.D., MBA
Chairman & CEO